Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Vanda Pharmaceuticals (VNDA) EBIAT (2016 - 2025)

Vanda Pharmaceuticals' EBIAT history spans 16 years, with the latest figure at -$141.2 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 2774.33% to -$141.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$220.5 million, a 1066.53% decrease, with the full-year FY2025 number at -$220.5 million, down 1066.53% from a year prior.
  • EBIAT hit -$141.2 million in Q4 2025 for Vanda Pharmaceuticals, down from -$22.6 million in the prior quarter.
  • Over the last five years, EBIAT for VNDA hit a ceiling of $9.7 million in Q2 2021 and a floor of -$141.2 million in Q4 2025.
  • Historically, EBIAT has averaged -$9.9 million across 5 years, with a median of -$1.1 million in 2023.
  • Biggest five-year swings in EBIAT: soared 1679.84% in 2021 and later crashed 3986.13% in 2024.
  • Tracing VNDA's EBIAT over 5 years: stood at $7.1 million in 2021, then dropped by 3.07% to $6.9 million in 2022, then tumbled by 134.98% to -$2.4 million in 2023, then crashed by 104.67% to -$4.9 million in 2024, then plummeted by 2774.33% to -$141.2 million in 2025.
  • Business Quant data shows EBIAT for VNDA at -$141.2 million in Q4 2025, -$22.6 million in Q3 2025, and -$27.2 million in Q2 2025.